Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cyclooxygenase-2 selective inhibitors, compositions and methods of use

a selective inhibitor and cyclooxygenase technology, applied in the field of new nitrosated and/or nitrosylated cyclooxygenase 2 (cox2) selective inhibitors, can solve the problems of undesirable side effects, gastrointestinal ulceration and renal toxicity, and the use of nsaids has been associated with adverse effects, so as to improve the cardiovascular profile of cox-2 selective inhibitors, the effect of unexpected potential for wound healing and anti-inflammatory properties

Inactive Publication Date: 2007-10-11
NICOX SA
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention provides novel COX-2 selective inhibitors that have potent analgesic, antiinflammatory, and wound healing properties. These compounds have reduced gastrointestinal toxicity and are safer than other COX-2 inhibitors. The invention also provides compositions containing these compounds and methods for their use in treating inflammation, pain, fever, gastrointestinal disorders, renal and respiratory toxicity, and COX-2-mediated disorders. The compounds can be nitrosated and / or nitrosylated, and can stimulate endogenous production of nitric oxide or be substrates for nitric oxide synthase. The invention also provides methods for using therapeutic agents, such as steroids, nonsteroidal antiinflammatory compounds, and other drugs, in combination with the nitrosated and nitrosylated COX-2 selective inhibitors.

Problems solved by technology

The chronic use of NSAIDs has been associated with adverse effects, such as gastrointestinal ulceration and renal toxicity.
The undesirable side effects are also due to the inhibition of prostaglandin in the affected organ.
However, these compounds can result in dyspepsia and can cause gastropathy (Mohammed et al, N. Engl. J. Med., 340(25) 2005 (1999)).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cyclooxygenase-2 selective inhibitors, compositions and methods of use
  • Cyclooxygenase-2 selective inhibitors, compositions and methods of use
  • Cyclooxygenase-2 selective inhibitors, compositions and methods of use

Examples

Experimental program
Comparison scheme
Effect test

example 1

1-(1-Cyclohexylmethyl-3-((nitrooxy)methyl)pyrazol-5-yl)-4-(methylsulfonyl)benzene

1a. N-((1Z)-1-Aza-2-cyclohexylvinyl)(tert-butoxy)carboxamide

[1162] Cyclohexane carboxaldehyde (5.0 g, 44.5 mmol) and t-butyl carbazate (5.89 g, 44.5 mmol) in methanol (140 mL) was stirred at room temperature for 1 hour. The solvent was evaporated and the resulting solid dried under vacuo to give a white solid in quantitative yield; mp 123-125° C. 1H NMR (300 MHz, CDCl3) δ 7.61 (bs, 1H), 7.02 (d, J=5.9 Hz, 1H), 2.22-2.39 (m, 1H), 1.60-1.89 (m, 5H), 1.49 (s, 9H), 1.19-1.47 (m, 5H); 13C NMR (75 MHz, CDCl3) δ 152.5, 151.5, 81.0, 40.7, 30.4, 28.5, 26.0, 25.6; mass spectrum (API-TIS) m / z 227 (MH+), 249 (MNa+). Anal. calcd for C12H22N2O2: C, 63.69; H, 9.80; N, 12.38. Found: C, 63.97; H, 9.76; N, 12.26.

1b. (tert-Butoxy)-N-((cyclohexylmethyl)amino)carboxamide

[1163] Sodium cyanoborohydride (2.8 g, 44.6 mmol) was added portionwise to a suspension of the product of Example 1a (10.1 g, 44.6 mmol) in 50% acetic a...

example 2

1-(1-Cyclohexylmethyl-3-((nitrooxy)methyl)pyrazol-5-yl)-4-(methylsulfonyl)benzene

2a. Methyl (2Z)-2-hydroxy-4-(4-(methylsulfonyl)phenyl)-4-oxobut-2-enoate

[1170] Sodium methoxide was prepared by dissolving Na (6.9 g, 30 mmol) in MeOH (400 mL). The solution was cooled to 0° C. Dimethyl oxalate (33 g, 280 mmol) was added followed by 1-(4-(methylsulfonyl)phenyl)ethan-1-one (28 g, 140 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 18 hours. The MeOH was evaporated and the residue triturated with 1N HCl (600 mL). The solid was collected on filter paper, washed with H2O (2×250), and dried in vacuo. This gave the title compound (39 g, 100%) as a tan solid. 1H-NMR (300 MHz, CDCl3) δ 8.17 (d, J=6.9 Hz, 2H), 8.09 (d, J=6.9 Hz, 2H), 7.10 (s, 1H), 3.97 (s, 3H), 3.10 (s, 3H).

2b. Methyl 1-(cyclohexylmethyl)-5-(4-(methylsulfonyl)phenyl)pyrazole-3-carboxylate

[1171] The product of Example 1c (8 mL, 23 mmol) and the product of Example 2a (4.5 g, 16 mmol) were ad...

example 3

4-(Methylsulfonyl)-1-(3-((nitrooxy)methyl)-1-benzylpyrazol-5-yl)benzene

3a. Methyl 5-(4-(methylthiophenyl)-1-benzylpyrazole-3-carboxylate

[1176] A mixture of the product Example 1d (2 g, 7.9 mmol) and benzylhydrazine hydrochloride (1.64 g, 10.3 mmol) in methanol (40 mL) and trifluoroacetic acid (0.5 mL) was heated at 70° C. for 2 hours and cooled to room temperature. The mixture was made basic with 5% Na2CO3 and extracted with EtOAc which was then washed with saturated NaHCO3 and water. The organic extracts were dried over Na2SO4 and the solvent was evaporated. The residue was recrystallized from CH2Cl2 / EtOAc / Hex to give the title compound as a white solid (1.88 g, 70%); mp 94-96° C. 1H NMR (300 MHz, CDCl3) δ 7.12-7.30 (m, 7H), 7.00-7.08 (m, 2H), 6.87 (s, 1H), 5.41 (s, 2H), 3.95 (s, 3H), 2.50 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 163.0, 145.2, 143.1, 140.6, 136.7, 129.4, 128.8, 127.9, 126.9, 126.3, 126.0, 109.4, 54.2, 52.2, 15.4; mass spectrum (API-TIS) m / z 339 (MH+), 307 (M-OCH3); Ana...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
body weightaaaaaaaaaa
temperatureaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The invention provides novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions and kits comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and / or at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and / or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and / or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and / or preventing renal and / or respiratory toxicity; for treating and / or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

Description

RELATED APPLICATIONS [0001] This application is a divisional of U.S. application Ser. No. 10 / 628,375, now allowed, which claims priority to U.S. Application No. 60 / 398,829 filed Jul. 29, 2002, the disclosures of which are incorporated by reference herein in their entireties.FIELD OF THE INVENTION [0002] The invention describes novel nitrosated and / or nitrosylated cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one nitrosated and / or nitrosylated cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and / or at least one therapeutic agent. The invention also provides novel compositions comprising at least one COX-2 selective inhibitor, that is optionally nitrosated and / or nitrosylated, and at least one compoun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/495A61K31/415C07D213/00C07D241/10A61K31/167A61K31/192A61K31/196A61K31/198A61K31/223A61K31/4015A61K31/405A61K31/422A61K31/427A61K31/4402A61K31/444A61K31/616A61K45/00A61P1/00A61P1/04A61P3/00A61P7/02A61P9/00A61P9/10A61P11/00A61P11/02A61P11/06A61P13/02A61P13/12A61P15/00A61P17/00A61P19/02A61P25/04A61P25/28A61P27/02A61P29/00A61P31/04A61P35/00A61P35/02A61P37/08A61P43/00C07D207/325C07D213/38C07D213/50C07D213/55C07D231/12C07D231/14C07D413/02C07D417/02
CPCC07D213/50C07D231/14C07D231/12C07D213/55A61P1/00A61P1/04A61P11/00A61P11/02A61P11/06A61P13/02A61P13/12A61P15/00A61P17/00A61P19/02A61P25/04A61P25/28A61P27/02A61P29/00A61P3/00A61P31/04A61P35/00A61P35/02A61P37/08A61P43/00A61P7/02A61P9/00A61P9/10
Inventor GARVEY, DAVID S.KHANAPURE, SUBHASH P.RANATUNGE, RAMANI R.RICHARDSON, STEWART K.SCHROEDER, JOSEPH D.
Owner NICOX SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com